NCT05717582View on ClinicalTrials.gov

Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Metastatic Prostate CancerCastration-Sensitive Prostate Cancer
Interventions
DRUG

apalutamide

Patients receive apalutamide 240mg,qd,po.

DRUG

androgen deprivation therapy

Patients receive systemic ADT.

PROCEDURE

cytoreductive radical prostatectomy with/without pelvic lymph node dissection

Patients receive cytoreductive radical prostatectomy with/without pelvic lymph node dissection.

RADIATION

metastasis-directed therapy with radiation

Patients receive metastasis-directed therapy with radiation guided by post-treatment oligopersistent metastases.

Trial Locations (2)

200000

Fudan University Shanghai Cancer Center Pudong Hospital, Shanghai

Fudan University Shanghai Cancer Center Xuhui Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT05717582 - Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment | Biotech Hunter | Biotech Hunter